Selected research
Industry Research
Thrombin (Human) Industry Research Report 2026
Market perspective
The global Thrombin (Human) market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Thrombin (Human) is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Thrombin (Human) is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Thrombin (Human) is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Thrombin (Human) include Shanghai RAAS, Hualan Biological, Bayer, Baxter, Vitrolife AB, Sigma-Aldrich Corporation, PromoCell GmbH, Octapharma and Life Technologies Corporation, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Thrombin (Human) market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Thrombin (Human) Market by Company
Shanghai RAAS
Hualan Biological
Bayer
Baxter
Vitrolife AB
Sigma-Aldrich Corporation
PromoCell GmbH
Octapharma
Life Technologies Corporation
Kedrion
Grifols
CSL
BD Biosciences
AMRESCO Inc
Thrombin (Human) Segment by Type
500IU/Vial
1000IU/Vial
2500IU/Vial
Thrombin (Human) Segment by Application
Biotechnology
Microbiology
Medicine
Others
Thrombin (Human) Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Thrombin (Human) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Thrombin (Human) and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Thrombin (Human).
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Thrombin (Human) manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Thrombin (Human) by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Thrombin (Human) in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- 500IU/Vial
- 1000IU/Vial
- 2500IU/Vial
Applications
- Biotechnology
- Microbiology
- Medicine
- Others
Companies covered
- Shanghai RAAS
- Hualan Biological
- Bayer
- Baxter
- Vitrolife AB
- Sigma-Aldrich Corporation
- PromoCell GmbH
- Octapharma
- Life Technologies Corporation
- Kedrion
- Grifols
- CSL
- BD Biosciences
- AMRESCO Inc
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Thrombin (Human) Market Size (2021-2032)
- 2.2.2 Global Thrombin (Human) Sales (2021-2032)
- 2.2.3 Global Thrombin (Human) Market Average Price (2021-2032)
- 2.3 Thrombin (Human) by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 500IU/Vial
- 2.3.3 1000IU/Vial
- 2.3.4 2500IU/Vial
- 2.4 Thrombin (Human) by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Biotechnology
- 2.4.3 Microbiology
- 2.4.4 Medicine
- 2.4.5 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Thrombin (Human) Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Thrombin (Human) Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Thrombin (Human) Revenue of Manufacturers (2021-2026)
- 3.4 Global Thrombin (Human) Average Price by Manufacturers (2021-2026)
- 3.5 Global Thrombin (Human) Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Thrombin (Human), Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Thrombin (Human), Product Type & Application
- 3.8 Global Manufacturers of Thrombin (Human), Established Date
- 3.9 Global Thrombin (Human) Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Shanghai RAAS
- 4.1.1 Shanghai RAAS Company Information
- 4.1.2 Shanghai RAAS Business Overview
- 4.1.3 Shanghai RAAS Thrombin (Human) Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Shanghai RAAS Thrombin (Human) Product Portfolio
- 4.1.5 Shanghai RAAS Recent Developments
- 4.2 Hualan Biological
- 4.2.1 Hualan Biological Company Information
- 4.2.2 Hualan Biological Business Overview
- 4.2.3 Hualan Biological Thrombin (Human) Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Hualan Biological Thrombin (Human) Product Portfolio
- 4.2.5 Hualan Biological Recent Developments
- 4.3 Bayer
- 4.3.1 Bayer Company Information
- 4.3.2 Bayer Business Overview
- 4.3.3 Bayer Thrombin (Human) Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Bayer Thrombin (Human) Product Portfolio
- 4.3.5 Bayer Recent Developments
- 4.4 Baxter
- 4.4.1 Baxter Company Information
- 4.4.2 Baxter Business Overview
- 4.4.3 Baxter Thrombin (Human) Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Baxter Thrombin (Human) Product Portfolio
- 4.4.5 Baxter Recent Developments
- 4.5 Vitrolife AB
- 4.5.1 Vitrolife AB Company Information
- 4.5.2 Vitrolife AB Business Overview
- 4.5.3 Vitrolife AB Thrombin (Human) Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Vitrolife AB Thrombin (Human) Product Portfolio
- 4.5.5 Vitrolife AB Recent Developments
- 4.6 Sigma-Aldrich Corporation
- 4.6.1 Sigma-Aldrich Corporation Company Information
- 4.6.2 Sigma-Aldrich Corporation Business Overview
- 4.6.3 Sigma-Aldrich Corporation Thrombin (Human) Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Sigma-Aldrich Corporation Thrombin (Human) Product Portfolio
- 4.6.5 Sigma-Aldrich Corporation Recent Developments
- 4.7 PromoCell GmbH
- 4.7.1 PromoCell GmbH Company Information
- 4.7.2 PromoCell GmbH Business Overview
- 4.7.3 PromoCell GmbH Thrombin (Human) Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 PromoCell GmbH Thrombin (Human) Product Portfolio
- 4.7.5 PromoCell GmbH Recent Developments
- 4.8 Octapharma
- 4.8.1 Octapharma Company Information
- 4.8.2 Octapharma Business Overview
- 4.8.3 Octapharma Thrombin (Human) Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Octapharma Thrombin (Human) Product Portfolio
- 4.8.5 Octapharma Recent Developments
- 4.9 Life Technologies Corporation
- 4.9.1 Life Technologies Corporation Company Information
- 4.9.2 Life Technologies Corporation Business Overview
- 4.9.3 Life Technologies Corporation Thrombin (Human) Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Life Technologies Corporation Thrombin (Human) Product Portfolio
- 4.9.5 Life Technologies Corporation Recent Developments
- 4.10 Kedrion
- 4.10.1 Kedrion Company Information
- 4.10.2 Kedrion Business Overview
- 4.10.3 Kedrion Thrombin (Human) Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Kedrion Thrombin (Human) Product Portfolio
- 4.10.5 Kedrion Recent Developments
- 4.11 Grifols
- 4.11.1 Grifols Company Information
- 4.11.2 Grifols Business Overview
- 4.11.3 Grifols Thrombin (Human) Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Grifols Thrombin (Human) Product Portfolio
- 4.11.5 Grifols Recent Developments
- 4.12 CSL
- 4.12.1 CSL Company Information
- 4.12.2 CSL Business Overview
- 4.12.3 CSL Thrombin (Human) Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 CSL Thrombin (Human) Product Portfolio
- 4.12.5 CSL Recent Developments
- 4.13 BD Biosciences
- 4.13.1 BD Biosciences Company Information
- 4.13.2 BD Biosciences Business Overview
- 4.13.3 BD Biosciences Thrombin (Human) Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 BD Biosciences Thrombin (Human) Product Portfolio
- 4.13.5 BD Biosciences Recent Developments
- 4.14 AMRESCO Inc
- 4.14.1 AMRESCO Inc Company Information
- 4.14.2 AMRESCO Inc Business Overview
- 4.14.3 AMRESCO Inc Thrombin (Human) Sales, Revenue and Gross Margin (2021-2026)
- 4.14.4 AMRESCO Inc Thrombin (Human) Product Portfolio
- 4.14.5 AMRESCO Inc Recent Developments
5 Global Thrombin (Human) Market Scenario by Region
- 5.1 Global Thrombin (Human) Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Thrombin (Human) Sales by Region: 2021-2032
- 5.2.1 Global Thrombin (Human) Sales by Region: 2021-2026
- 5.2.2 Global Thrombin (Human) Sales by Region: 2027-2032
- 5.3 Global Thrombin (Human) Revenue by Region: 2021-2032
- 5.3.1 Global Thrombin (Human) Revenue by Region: 2021-2026
- 5.3.2 Global Thrombin (Human) Revenue by Region: 2027-2032
- 5.4 North America Thrombin (Human) Market Facts & Figures by Country
- 5.4.1 North America Thrombin (Human) Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Thrombin (Human) Sales by Country (2021-2032)
- 5.4.3 North America Thrombin (Human) Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Thrombin (Human) Market Facts & Figures by Country
- 5.5.1 Europe Thrombin (Human) Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Thrombin (Human) Sales by Country (2021-2032)
- 5.5.3 Europe Thrombin (Human) Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Thrombin (Human) Market Facts & Figures by Country
- 5.6.1 Asia Pacific Thrombin (Human) Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Thrombin (Human) Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Thrombin (Human) Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Thrombin (Human) Market Facts & Figures by Country
- 5.7.1 South America Thrombin (Human) Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Thrombin (Human) Sales by Country (2021-2032)
- 5.7.3 South America Thrombin (Human) Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Thrombin (Human) Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Thrombin (Human) Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Thrombin (Human) Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Thrombin (Human) Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Thrombin (Human) Sales by Type (2021-2032)
- 6.1.1 Global Thrombin (Human) Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Thrombin (Human) Sales Market Share by Type (2021-2032)
- 6.2 Global Thrombin (Human) Revenue by Type (2021-2032)
- 6.2.1 Global Thrombin (Human) Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Thrombin (Human) Revenue Market Share by Type (2021-2032)
- 6.3 Global Thrombin (Human) Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Thrombin (Human) Sales by Application (2021-2032)
- 7.1.1 Global Thrombin (Human) Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Thrombin (Human) Sales Market Share by Application (2021-2032)
- 7.2 Global Thrombin (Human) Revenue by Application (2021-2032)
- 7.2.1 Global Thrombin (Human) Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Thrombin (Human) Revenue Market Share by Application (2021-2032)
- 7.3 Global Thrombin (Human) Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Thrombin (Human) Value Chain Analysis
- 8.1.1 Thrombin (Human) Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Thrombin (Human) Production Mode & Process
- 8.2 Thrombin (Human) Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Thrombin (Human) Distributors
- 8.2.3 Thrombin (Human) Customers
9 Global Thrombin (Human) Analyzing Market Dynamics
- 9.1 Thrombin (Human) Industry Trends
- 9.2 Thrombin (Human) Industry Drivers
- 9.3 Thrombin (Human) Industry Opportunities and Challenges
- 9.4 Thrombin (Human) Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst